SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ciompi L. The natural history of schizophrenia in the long term. Br. J. Psychiatry 1980; 136: 413420.
  • 2
    Kane JM. Schizophrenia. N. Engl. J. Med. 1996; 334: 3441.
  • 3
    Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988; 45: 789796.
  • 4
    Ishigooka J, Murasaki M, Miura S. Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group. Psychiatry Clin. Neurosci. 2000; 54: 467478.
  • 5
    Conley RR, Tamminga CA, Bartko JJ et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J. Psychiatry 1998; 155: 914920.
  • 6
    Shen WW. The metabolism of atypical antipsychotic drugs: An update. Ann. Clin. Psychiatry 1999; 11: 145158.
  • 7
    Tollefson GD, Birkett MA, Kiesler GM, Wood AJ and Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry 2001; 49: 5263.
  • 8
    Bronson BD, Lindenmayer JP. Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia. J. Clin. Psychopharmacol. 2000; 20: 382384.
  • 9
    Mountjoy CQ, Baldacchino AM, Stubbs JH. British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am. J. Psychiatry 1999; 156: 158159.
  • 10
    Sheitman BB, Lindgren JC, Early J, Sved M. High-dose olanzapine for treatment-refractory schizophrenia. Am. J. Psychiatry 1997; 154: 1626.
  • 11
    Martin J, Gomez JC, Garcia-Bernardo E, Cuesta M, Alvarez E, Gurpegui M. Olanzapine in treatment-refractory schizophrenia: Results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J. Clin. Psychiatry 1997; 58: 479483.
  • 12
    Chang WH, Jann MW, Hwu HG et al. Ethnic comparison of haloperidol and reduced haloperidol plasma levels: Taiwan Chinese versus American non-Chinese. J. Formos. Med. Assoc. 1991; 90: 572578.
  • 13
    Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol. Bull. 1988; 24: 6267.
  • 14
    Overall JE, Beller SA. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research. I. Factor structure on an inpatient unit. J. Gerontol. 1984; 39: 187193.
  • 15
    Guy W. Early Clinical Drug Evaluation Unit Assessment Manual for Psychopharmacology, Revised Edition. Department of Health, Education and Welfare, Washington DC, 1976
  • 16
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261276.
  • 17
    Anonymous. Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol. Bull. 1988; 24: 781783.
  • 18
    Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970; 212: 1119.
  • 19
    Barnes TR. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989; 154: 672676.
  • 20
    Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the Japan multicenter, double-blind olanzapine trial. Psychiatry Clin. Neurosci. 2001; 55: 403414.
  • 21
    Ishigooka J, Murasaji M, Miura S and The Olanzapine Early-Phase, I. I. Study Group. Efficacy and safety of olanzapine, and atypical antipsychotic, in patients with schizophrenia: Results of an open-label multicenter study in Japan. Psychiatry Clin. Neurosci. 2001; 55: 353363.
  • 22
    Ishigooka J, Murasaki M, Miura S and the Olanzapine Late-Phase, I. I. Study Group. Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients. Psychiatry Clin. Neurosci. 2000; 54: 467478.
  • 23
    Taylor D, Drummond S, Pendlebury J. Olanzapine in practice. Psychiatr. Bull. 1998; 22: 552554.
  • 24
    Kasper S. Risperidone and olanzapine: Optimal dosing for efficacy and tolerability in patients with schizophrenia. Int. Clin. Psychopharmacol. 1998; 13: 253262.
  • 25
    Chiu H, Lee S, Leung CM, Wing YK. Neuroleptic prescription for Chinese schizophrenics in Hong Kong. Aust. N.Z. J. Psychiatry 1992; 26: 262264.
  • 26
    Jann MW, Chang WH, Lam YW et al. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations. Prog. Neuropsychopharmacol. Biol. Psychiatry 1992; 16: 193202.
  • 27
    Potkin SG, Shen Y, Pardes H et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res. 1984; 12: 167172.
  • 28
    Jann MW, Chang WH, Davis CM et al. Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients. Psychiatry Res. 1989; 30: 4552.
  • 29
    Volavka J, Czobor P, Sheitman B et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry 2002; 159: 255262.
  • 30
    Littrell KH, Johnson CG, Hilligoss NM, Peabody CD, Littrell SH. Switching clozapine responders to olanzapine. J. Clin. Psychiatry 2000; 61: 912915.
  • 31
    Delassus-Guenault N, Jegouzo A, Odou P et al. Clozapine-olanzapine: A potentially dangerous switch. A report of two cases. J. Clin. Pharm. Ther. 1999; 24: 191195.
  • 32
    Kraus T, Haack M, Schuld A et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. J. Psychiatry 1999; 156: 312314.
  • 33
    Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine. Am. J. Psychiatry 1999; 156: 970.
  • 34
    Lindenmayer JP, Smith RC, Singh A, Parker B, Chou E, Kotsaftis A. Hyperglycemia in patients with schizophrenia who are treated with olanzapine. J. Clin. Psychopharmacol. 2001; 21: 351353.
  • 35
    Goldstein LE, Sporn J, Brown S et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438443.
  • 36
    Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol. Psychiatry 1998; 44: 778783.
  • 37
    Von Hayek D, Huttl V, Reiss J, Schweiger HD, Fuessl HS. [Hyperglycemia and ketoacidosis associated with olanzapine]. Nervenarzt 1999; 70: 836837.
  • 38
    Seaburg HL, McLendon BM, Doraiswamy PM. Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: Case report and review of literature. Pharmacotherapy 2001; 21: 14481454.
  • 39
    Ragucci KR, Wells BJ. Olanzapine-induced diabetic ketoacidosis. Ann. Pharmacother. 2001; 35: 15561558.